To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Recombinant Influenza Vac… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Recombinant Influenza Vaccines: Saviors to Overcome Immunodominance

Review article
Authors Nimitha Rose Mathew
Davide Angeletti
Published in Frontiers in Immunology
Volume 10
ISSN 1664-3224
Publication year 2020
Published at Institute of Biomedicine, Department of Microbiology and Immunology
Language en
Keywords influenza A virus; immunodominance; vaccines; B cells; antibodies
Subject categories Immunology


It has been almost a decade since the 2009 influenza A virus pandemic hit the globe causing significant morbidity and mortality. Nonetheless, annual influenza vaccination, which elicits antibodies mainly against the head region of influenza hemagglutinin (HA), remains as the mainstay to combat and reduce symptoms of influenza infection. Influenza HA is highly antigenically variable, thus limiting vaccine efficacy. In addition, the variable HA head occupies the upper strata of the immunodominance hierarchy, thereby clouding the antibody response toward subdominant epitopes, which are usually conserved across different influenza strains. Isolation of monoclonal antibodies from individuals recognizing such epitopes has facilitated the development of recombinant vaccines that focus the adaptive immune response toward conserved, protective targets. Here, we review some significant leaps in recombinant vaccine development, which could possibly help to overcome B cell and antibody immunodominance and provide heterosubtypic immunity to influenza A virus.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?